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We have shown previously (Villalonga, P., López-
Alcalá, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil,
J., Marais, R., Marshall, C. J., Bachs, O., and Agell, N.
(2001) Mol. Cell. Biol. 21, 7345–7354) that calmodulin neg-
atively regulates Ras activation in fibroblasts. Hence,
anti-calmodulin drugs (such as W13, trifluoroperazine,
or W7) are able to induce Ras/ERK pathway activation
under low levels of growth factors. We show here that
cell treatment with protein kinase C (PKC) inhibitors
abolishes W13-induced activation of Ras, Raf-1, and
ERK. Consequently, PKC activity is essential for achiev-
ing the synergism between calmodulin inhibition and
growth factors to activate Ras. Furthermore, whereas
the activation of PKC by 12-O-tetradecanoylphorbol-13-
acetate (TPA) does not induce Ras activation in 3T3
cells, activation is observed if calmodulin is simulta-
neously inhibited. This indicates that calmodulin is pre-
venting Ras activation by PKC. Treatment of cells with
epidermal growth factor receptor or platelet-derived
growth factor receptor tyrosine kinase inhibitors does
not abrogate the activation of Ras by calmodulin inhi-
bition. This implies that epidermal growth factor recep-
tor and platelet-derived growth factor receptor tyrosine
kinase activities are dispensable for the activation of
Ras by TPA plus W13, and, therefore, Ras activation is
not a consequence of the transactivation of those recep-
tors by the combination of the anti-calmodulin drug plus
TPA. Furthermore, K-Ras, the isoform previously shown
to bind to calmodulin, is the only one activated by TPA
when calmodulin is inhibited. These data suggest that
direct interaction between K-Ras and calmodulin may
account for the inability of PKC to activate Ras in 3T3
fibroblasts. In vitro experiments showed that the phos-
phorylation of K-Ras by PKC was inhibited by calmod-
ulin, suggesting that calmodulin-dependent modulation
of K-Ras phosphorylation by PKC could be the mecha-
nism underlying K-Ras activation in fibroblasts treated
with TPA plus W13.
The three members of the Ras family of small GTPases, H-,
N-, and K-Ras, are key regulators of signal transduction path-
ways that control cell proliferation, differentiation, survival,
and apoptosis (1–3). The molecular basis for such a great vari-
ety of cell responses controlled by Ras proteins relies on the fact
that Ras is able to transduce signals from different extracellu-
lar stimuli, including growth factors, hormones, and cell-extra-
cellular matrix contacts to many downstream effectors (4, 5).
As a molecular switch, Ras cycles between a GTP-bound active
and an inactive state when GTP is hydrolyzed to GDP. Active
Ras interacts with and modulates the activity of effector pro-
teins. The best characterized Ras effector is the serine/threo-
nine kinase Raf, which leads to the activation of the extracel-
lular signal-regulated kinase (ERK)1 pathway that plays a
major role in cell proliferation and differentiation (6–8). Other
effectors for Ras include the lipid kinase phosphatidylinositol-
3-kinase (PI3K), which is involved in cell survival, prolifera-
tion, and metabolism (9–11), and the nucleotide exchange fac-
tors for Ral GTPase, RalGDS, Rlf, and Rlg (12).
Many molecules have been described as influencing the Ras
GTP/GDP cycle, mainly through two distinct biochemical ac-
tivities: 1) the guanine nucleotide exchange factors (GEFs) that
regulate the replacement of the nucleotide bound to Ras, favor-
ing the GTP-bound active state; or 2) the GTPase-activating
proteins (GAPs), which increase Ras low intrinsic GTPase ac-
tivity and thereby promote its inactivation. Following extracel-
lular stimulation, GEFs are recruited to the plasma membrane
through binding to a set of molecular adaptors, inducing tran-
siently Ras-GTP complexes (13, 14). Distinct signals such as
those transduced from tyrosine kinase receptors, G protein-
coupled receptors, or integrin-induced cell attachment to the
extracellular matrix all lead to Ras activation. In many cases
this is achieved through the membrane recruitment of the
Sos exchange factor, which in turn depends on the adaptor
protein Grb-2. Autophosphorylation of tyrosine kinase recep-
tors or activation of a variety of non-receptor tyrosine kinases
such as Src, Pyk-2, or focal adhesion kinase in response to the
activation of diverse G protein-coupled receptors or cell-
extracellular matrix engagement all create phosphotyrosine
residues that allow Grb-2/Sos binding and thus its recruit-
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ment to the vicinity of Ras at the plasma membrane, leading
to its activation (15, 16).
In addition, other mechanisms are able to link extracellular
signals to Ras activation, such as phospholipase C activation
and its consequent increase in diacylglycerol and intracellular
Ca2. Ca2 induces the activation of RasGRF, another Ras
guanine nucleotide exchange factor present mainly in neurones
that lead to Ras activation (17). In addition, together with
diacylglycerol, Ca2 is also able to activate RasGRPs, a Ras-
GEF family present in lymphocytes and neurones (18). In turn,
protein kinase C (PKC) activation by diacylglycerol is also able
to activate Ras in some cellular types. The activation of Ras
through PKC-dependent GAP inhibition has been reported in T
lymphocytes upon T cell receptor activation (19). However, this
seems not to be the case for fibroblasts (20), although PKC is
able to induce Ras activation in B lymphocytes and COS cells
(21). GAP activity can also be regulated by binding to phospho-
rylated tyrosine kinase receptors (22). In summary, a highly
interconnected network of multiple pathways regulates Ras
activation in response to extracellular signals.
The Ca2-binding protein calmodulin (CaM), which acts as a
second messenger in cellular signal transduction pathways and
regulates cell proliferation (23–26), has been shown to be one of
the molecules involved in the modulation of Ras activity. We
have shown that CaM down-regulates the Ras/Raf/MEK/ERK
pathway in fibroblasts (27, 28), and other groups have shown
that CaM is able to inhibit in vitro EGFR (29) activity and the
shedding of EGF-like growth factors (30). Although low doses of
growth factors are not able to induce activation of the Ras/Raf/
MEK/ERK pathway in fibroblasts, activation is observed if
CaM is simultaneously inhibited, indicating that CaM is pre-
venting the activation of this pathway under basal conditions.
Furthermore, CaM inhibition in fibroblasts leads to a more
sustained level of ERK activation following serum stimulation.
CaM functions are mediated by its association with specific
target proteins named CaM-binding proteins (CaMBPs), which
are regulated upon CaM binding (31, 32). We have recently
demonstrated that K-RasB is a CaMBP and that this Ras
isoform is specifically activated when serum-starved NIH3T3
cells are treated with a CaM inhibitor, suggesting a direct
relation between CaM binding to Ras and Ras inhibition by
CaM (28). However, the activation of Ras by CaM inhibition is
low in the absence of growth factors, increasing dramatically in
the presence of low levels of mitogens. We have analyzed here
the intracellular elements that are cooperating with CaM in-
hibition to induce Ras activation. Our results show that PKC
activity is responsible for this synergism and that CaM is
preventing the activation of Ras by PKC in 3T3 fibroblasts.
EXPERIMENTAL PROCEDURES
Cell Culture—NIH3T3 cells were grown in Dulbecco’s minimum es-
sential medium supplemented with 10% donor calf serum and made
quiescent by culturing them for 24 h with media containing 0.5% fetal
bovine serum (FBS). Swiss 3T3 cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS and made qui-
escent by incubating 1  104 cells/cm2 until confluence (6–8 days) and
keeping them in 0.5% FBS medium overnight during the last day and in
serum-free medium for the last 3 h. Purified growth factors (EGF,
PDGF or bombesin), 10% FBS, TPA, or drugs (W12, W13, GF109203X,
Ro-0432, AG1296, or AG1478) were added directly to the media at the
indicated concentrations, and cells were harvested at the time points
indicated in the results.
Gel Electrophoresis and Immunoblotting—Cells were lysed in a
buffer containing 2% SDS, 67 mM Tris-HCl, pH 6.8, and 10 mM EDTA,
and sonicated twice for 10 s. Protein content was measured by the
Lowry procedure using bovine serum albumin as standard. These cel-
lular extracts or proteins from pull-down experiments were electro-
phoresed in SDS-polyacrylamide gels essentially as described (33). Af-
ter electrophoresis, the proteins were transferred to Immobilon-P strips
for 2 h at 60 V. The sheets were preincubated in TBS (20 mM Tris-HCl,
pH 7.5, 150 mM NaCl), 0.05% Tween 20, and 5% defatted milk powder
for 1 h at room temperature and then incubated for 1 h at room
temperature in TBS, 0.05% Tween 20, 1% bovine serum albumin and
0.5% defatted milk powder containing the following appropriated anti-
bodies: ERK2 (Upstate Biotechnology, catalog no. 0-157; 1:500 dilution),
Pan-Ras (Oncogene Science OP40, 1:100 dilution), N-Ras (Santa Cruz
Biotechnology, catalog no. sc-31; 1:100 dilution), K-Ras (Santa Cruz,
catalog no. sc-30; 1:100 dilution) monoclonal antibodies and H-Ras
(Santa Cruz Biotechnology, catalog no. sc-520, 1:100 dilution), and
phospho-ERK1/2 (Cell Signaling Tech, catalog no. 9101; 1:500 dilution)
polyclonal antibodies. After washing in TBS with 0.05% Tween 20
(three times, 10 min each), the sheets were incubated with a peroxi-
dase-coupled secondary antibody (1:2000 dilution) (Bio-Rad) for 1 h at
room temperature. After incubation, the sheets were washed twice in
TBS with 0.05% Tween 20 and once in TBS. The reaction was visualized
by ECL (Amersham Biosciences) or Super-Signal (Pierce). Images were
then scanned, and intensities were quantified using the Quantity One
program (Bio-Rad).
Measurement of Ras Activation—The capacity of Ras-GTP to bind to
RBD (Ras-binding domain of Raf-1) was used to analyze the amount of
active Ras (34). Cells (5–10  106) were lysed in the culture dish with
Ras extraction buffer (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM
NaCl, 5 mM MgCl2, 1% (v/v) Triton X-100, 5 mM NaF, 10% (v/v) glycerol,
and 0.5% (v/v) 2-mercaptoethanol) plus protease and phosphatase in-
hibitors. Cleared (10,000  g) lysate was assayed for protein concen-
tration by the Bradford method, and protein-equalized supernatants
were incubated for 2 h at 4 °C with glutathione-Sepharose 4B beads
pre-coupled with GST-RBD (1 h at 4 °C). The beads were washed four
times in the lysis buffer. Bound proteins were solubilized by the addi-
tion of 30 l of Laemmli loading buffer and run on 12.5% SDS-PAGE
gels. The amount of Ras in the bound fraction was analyzed by Western
blotting.
Raf-1 Kinase Activity Assays—To measure Raf-1 activity, kinase
assays following immunoprecipitation were performed essentially as
described (35). Briefly, treated cells (2  106) were harvested on ice in
40 l of extraction buffer (20 mM Tris-HCl, pH 7.5, 1.5 M KCl, 1 mM
EDTA, 5% (v/v) glycerol, 1% (v/v) Triton X-100, and 5 mM NaF plus
protease and phosphatase inhibitors), diluted with 260 l of dilution
buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v)
Triton X-100, and 5 mM NaF plus protease and phosphatase inhibitors),
and clarified by centrifugation (10,000  g). Supernatants (equalized
for protein concentration) were then immunoprecipitated for 2 h at 4 °C
with 2 g of anti-Raf-1 (Transduction Laboratories, R-19120) pre-cou-
pled with 20 l of protein G-Sepharose (Sigma) for 2 h at room temper-
ature. Immunoprecipitates were then washed three times in wash
buffer (30 mM Tris, 0.1 mM EDTA, 0.3% 2-mercaptoethanol, 10% glyc-
erol, 1% (v/v) Triton X-100, 5 mM NaF, 0.2 mM Na3VO4) with decreasing
amounts of NaCl (high, 1 M; low, 0.1 M and salt-free). Washed immu-
noprecipitates were incubated for 30 min at 30 °C in 20 l of MEK
buffer (30 mM Tris, 0.1 mM EDTA, 0.3% 2-mercaptoethanol, 10 mM
MgCl2, 0.1% (v/v) Triton X-100, 5 mM NaF, 0.2 mM Na3VO4, 0.8 mM
ATP, 6.5 g/ml GST-MEK, and 100 g/ml GST-ERK2), and the reaction
was terminated by the addition of 20 l of ice-cold Kill buffer (30 mM
Tris, 6 mM EDTA, 0.3% 2-mercaptoethanol, 0.1% (v/v) Triton X-100, 5
mM NaF, 0.2 mM Na3VO4). Following centrifugation, 6 l of superna-
tants (triplicates) were incubated for 15 min at 30 °C with 24 l of
myelin basic protein (MBP) buffer (50 mM Tris, 0.1 mM EDTA, 0.3%
2-mercaptoethanol, 10 mM MgCl2, 0.1% (v/v) Triton X-100, 5 mM NaF,
0.2 mM Na3VO4, 0.1 mM ATP, 50 Ci/ml [-
32P]ATP, 0.5 g/l MBP
(Sigma), 0.16 g/l bovine serum albumin), and then 24 l of this
reaction mixture were loaded on P81 sheets (Millipore) and washed
three times (20 min each) in 75 mM orthophosphoric acid. Remaining
radioactivity was then counted on a Cerenkov counter.
In Vitro Phosphorylation—3 g of purified baculovirus-expressed
K-Ras-GST (28) were incubated with a mixture containing 25 mM
Hepes, pH 7.5, 10 mM MgCl2, 2 mM dithiothreitol, and 25 M ATP in the
presence or absence of CaM (7 g) and in the presence of either CaCl2
(1 M) or EGTA (1 mM) in a final volume of 30 l. The reaction was
initiated by adding 0.25 l of rat brain PKC catalytic fragment (Biomol)
and [-32P]ATP (3000 Ci/mmol) (Amersham Biosciences). Samples were
incubated at 30 °C for 30 min, and the reaction was stopped by the
addition of Laemmli sample buffer. Samples were electrophoresed on
polyacrylamide SDS gel electrophoresis. The gel was stained with Coo-
massie Blue, destained, and dried. The digital data were obtained with
a Bio-Rad phosphorimaging device.
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RESULTS
ERK Activation Induced by CaM Inhibition in Fibroblasts Is
Dependent on PKC Activity—We have shown previously that
the addition of anti-CaM drugs synergies with low concentra-
tions of FCS, EGF, PDGF, or bombesin to induce ERK1/2
activation in 3T3 cells (27, 28). The presence of low levels of
these factors was essential for observing the activation of ERK
by treatment of the cells with CaM inhibitors. We therefore
hypothesized that these different stimuli were all able to acti-
vate a signaling pathway that was able to cooperate with CaM
inhibition to induce ERK activation. One signaling event that
is turned on by the majority of growth factors described so far
is the activation of isotypes of the PKC family of serine/threo-
nine kinases, especially the conventional PKCs that are acti-
vated by diacylglycerol and the phorbol ester class of tumor
promoters. We analyzed whether PKC was essential to induce
ERK activation by CaM inhibitors. W13 (15 g/ml) was used to
inhibit CaM, and W12 (15 g/ml) was used as a control drug.
We have observed the same effect on ERK activation with other
anti-CaM drugs such as trifluoroperazine or W7 (28). As shown
in Fig. 1 and in agreement with previous results, neither FCS
nor bombesin was able to induce a significant ERK phospho-
rylation when added at the indicated concentrations to serum-
starved Swiss 3T3 under control conditions (W12). When CaM
was inhibited by treating the cells at the same time with W13,
the activation of ERK was observed. To analyze a possible role
for PKC on ERK activation by CaM inhibition, cells were si-
multaneously treated with a broadly used PKC inhibitor,
GF109203X (5 M). As observed in Fig. 1, the activation of ERK
by W13 was completely abolished in the presence of the PKC
inhibitor. Similar results were obtained with NIH3T3 cells
(Fig. 2, A and C). Although the addition of W13 but not the
control drug W12 to serum-starved (0.5% FCS) cells induced
ERK phosphorylation, no phosphorylation was observed when
PKC was inhibited by either GF109203X (5 M) or Ro-4320 (5
M). In contrast, 10% FCS-induced ERK activation was not
FIG. 1. ERK activation induced by CaM inhibition in Swiss 3T3
fibroblasts is dependent on PKC activity. A, quiescent Swiss 3T3
fibroblasts were treated for 15 min with 10% FCS and W12 (15 g/ml)
or W13 (15 g/ml) together with 0.5% FCS or 0.05 nM bombesin in the
absence () or presence () of GF109203X (5 M). ERK activation was
analyzed by Western blotting using anti-phospho-ERK specific antibod-
ies (P-ERK; upper panel). As a control of the amount of protein, total
ERK2 was also analyzed in the same samples (lower panel). B, quanti-
fication of three different experiments as described in A. Quantification
of ERK phosphorylation by 0.5% FCS is also included.
FIG. 2. ERK activation induced by CaM inhibition in NIH3T3
fibroblasts is dependent on PKC activity. A, quiescent NIH3T3
cells incubated with 0.5% FCS were treated for 15 min with 10% FCS,
W12 (15 g/ml), or W13 (15 g/ml) in the absence or presence (where
indicated) of Ro-0432 (5 M) or GF109203X (5 M). B, NIH3T3 cells
were serum-deprived in 0.5% FCS-containing medium for 24 h in the
absence or presence (where indicated) of TPA (500 nM) and then treated
for 15 min with PDGF (0.4 nM), W12 (15 g/ml), W13 (15 g/ml), or TPA
(100 nM). ERK activation was analyzed in the upper panels of A and B
by Western blotting using anti-phospho-ERK-specific antibodies. As a
control, total ERK2 was also analyzed in those samples (lower panels).
C, the quantification of three different experiments as the ones shown
in A. Quantification of ERK phosphorylation by 0.5% FCS and the effect
of GF109203X on 10% FCS-induced ERK phosphorylation are also
included.
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inhibited by GF109203X (Fig. 2C). To further confirm PKC
participation, serum-deprived (0.5% FCS) NIH3T3 cells were
treated for 24 h with TPA (500 nM) to induce a depletion of the
phorbol ester-sensitive class of PKCs (36). Cells were then
treated with PDGF (0.4 nM) as a positive control or with W13 or
W12. As shown in Fig. 2B, chronic TPA treatment completely
prevented the activation of ERK induced by W13. In contrast,
the activation induced by PDGF was only partially reduced.
Altogether, these results suggested that PKC activity was es-
sential for the activation of ERK by W13 at low doses of growth
factors.
Raf-1 and Ras Activation Induced by CaM Inhibition in
Fibroblasts Is Dependent on PKC Activity—We also showed
previously that the treatment of cultured fibroblasts with W13
induced not only ERK activation but also Ras, Raf-1, and MEK
activation (27). The relationship between PKC and the Ras/Raf/
MEK/ERK signaling pathway is complex and not completely
understood, because different members of the pathway have
been shown to be activated by PKCs in distinct cell systems.
Consequently, it was difficult to infer directly at what level of
the pathway the synergism between PKC activity and CaM
inhibition was taking place. To better understand this, the
effect of PKC inhibition on the activation of Raf-1 and Ras
induced by W13 was analyzed. When serum-deprived (0% FCS)
NIH3T3 cells were treated with either W12 or W13, no activa-
tion of Raf-1 was observed. As a positive control, cells were
treated with PDGF (1 nM) and a 3-fold activation was observed
on Raf-1 kinase activity. W13 treatment in the presence of 0.5%
FCS induced an increase in Raf-1 activity that was not ob-
served in the complete absence of FCS and was lower in W12-
treated cells. This increase in Raf-1 activity was abolished
in the presence of GF109203X (Fig. 3). These results indicate
that Raf-1 activation induced by CaM inhibition is also
PKC-dependent.
We then tested to see whether the previously described ac-
tivation of Ras by W13 was also sensitive to the presence of
PKC inhibitors. To clarify this issue, serum-starved (either 0 or
0.5% FCS) NIH3T3 cells were treated with the anti-CaM drug
(W13) or the control drug (W12), and Ras activation was ana-
lyzed by the GST-Raf-1-RBD pull-down method. As shown in
Fig. 4, A and D, CaM inhibition induced a low activation of Ras
in 0% FCS-starved cells. This activation was clearly higher in
cells starved in 0.5% FCS-containing media. Although low, the
activation at 0% FCS was reproducible, and the activation at
0.5% FCS was comparable with the one obtained with PDGF (1
nM). Again, this suggested that W13 was cooperating with some
factor that was already activated at basal levels in 0% FCS-
starved cells and at higher levels in 0.5% FCS-starved cells to
allow the activation of Ras. The inhibition of PKC by
GF109203X treatment completely blocked the activation of Ras
induced by W13 (Fig. 4, A and D), indicating that Ras activa-
tion by W13 was PKC-dependent.
PKC Activation Alone Is Sufficient to Induce Ras Activation
When CaM Is Inhibited—These results place PKC activity as a
strong candidate to be the signaling event that, in a cooperative
fashion with CaM inhibition, is essential for inducing Ras
activation at low levels of growth factors. To determine
whether PKC was in fact this key signaling element supplied
up to now by different growth factors, we tested to see whether
PKC activation alone, in a serum-free background, was enough
to induce Ras activation when CaM was inhibited. To do this,
serum-starved NIH3T3 cells were acutely treated with TPA
(100 nM) in the absence or presence of W13 (Fig. 4, B and D). As
described previously (20), TPA treatment of NIH3T3 cells did
not change the basal levels of Ras activation significantly. As
shown previously, treatment of these cells with W13 alone
induced only a slight activation of Ras. Interestingly, when
both W13 and TPA were added together a strong synergism
was observed, and the levels of active Ras reached values
comparable with the ones induced by PDGF treatment (Fig. 4,
B and D). Similar results were obtained using Swiss 3T3 fibro-
blasts (data not shown). Furthermore, this activation was not
observed when cells were simultaneously treated with PKC
inhibitors (Ro-0432 or GF109203X) (Fig. 4, C and D). Alto-
gether, these data point to the fact that CaM is preventing the
activation of Ras by PKC in 3T3 fibroblasts.
Activation of Ras by W13 Treatment Does Not Require EGF
or PDGF Receptor Activity—Calmodulin inhibitors have been
shown to induce the cleavage of membrane-bound proteins
leading to tyrosine kinase receptor transactivation, which, in
some cases such as the shedding of pro-HB-EGF by metallo-
protease disintegrins, is a PKC-dependent process (37–39). We
investigated the possibility that TPA, together with W13, was
transactivating the EGF or the PDGF receptors and, only as an
indirect consequence, inducing Ras activation. To this end, the
same experiment depicted in Fig. 3 was performed, but in this
case the cells were pre-treated with EGFR or PDGFR tyrosine
kinase inhibitors. As shown in Fig. 5, Ras activation induced by
TPA (100 nM) plus W13 treatment was not inhibited by pre-
incubating the cells with either AG1296 (PDGFR kinase inhib-
itor) or AG1478 (EGFR kinase inhibitor). As expected, AG1296
was able to inhibit the activation of Ras by PDGF, and AG1478
did so with EGF-induced Ras activation. Genistein (100 M), a
more general tyrosine-kinase inhibitor, had a strong inhibitory
effect on EGF-induced ERK activation (70%) but a low inhibi-
tory effect on TPA plus W13-induced ERK activation (30%).
These results indicate that the activation of Ras induced by
TPA plus W13 was not mainly dependent on EGFR or PDGFR
kinase activities.
K-Ras Is the Ras Isoform Activated by CaM Inhibition in the
Presence of TPA—We have shown previously that one of the
Ras isoforms, K-Ras, is a CaMBP. Furthermore, this isoform is
the one specifically activated when CaM is inhibited in serum-
starved (0.5% FCS) NIH3T3 cells (28). This favored the hypoth-
esis that the interaction between K-Ras and CaM was, in fact,
modulating K-Ras activity. If the element synergizing with
W13 inhibition to induce Ras activation was PKC, one should
FIG. 3. Raf-1 activation induced by CaM inhibition in fibro-
blasts is dependent on PKC activity. NIH3T3 cells were serum-
deprived for 24 h in serum-free medium () or 0.5% FCS-containing
medium () and then treated for 10 min with PDGF (1 nM), W12 (15
g/ml), or W13 (15 g/ml) in the absence () or presence () of
GF109203X (5 M). Cell lysates were immunoprecipitated with anti-
Raf-1 antibodies, and the kinase activity of the immunoprecipitates was
assayed in a two-step assay against GST-MEK/GST-ERK2 in the first
step and MBP in the second one. The mean kinase activity (in cpm) of
three replicates for each condition is represented. This is a represent-
ative experiment of three independent ones.
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expect that treatment with TPA plus W13 would also activate
K-Ras specifically. Serum-starved (0% FCS) NIH3T3 cells were
treated for 5 min with TPA (100 nM) plus W13 or the control
drug W12, and activation of the different Ras isoforms was
analyzed by RBD pull-down followed by a Western blot with
Ras isoform-specific antibodies. As shown in Fig. 6, the TPA
plus W13 treatment induced K-Ras activation specifically.
In Vitro K-Ras Phosphorylation Is Inhibited by CaM—A di-
rect link between K-Ras and PKC was established several
years ago when Ballester et al. (51) showed that K-Ras could be
phosphorylated in vitro by PKC. To test whether CaM could
modulate this phosphorylation, K-Ras-GST and H-Ras-GST
expressed in baculovirus were phosphorylated in vitro by the
catalytic subunit of PKC in the presence or absence of CaM. As
described previously, K-Ras was phosphorylated by PKC,
whereas H-Ras phosphorylation was almost undetectable (Fig.
7). Interestingly, phosphorylation was inhibited when CaM
was added. Furthermore, the inhibition was reverted if phos-
phorylation was performed in the absence of Ca2 (plus EGTA),
an experimental condition that does not allow binding of CaM
to K-Ras (28).
DISCUSSION
An emerging theme in signal transduction is the fact that the
activation of a pathway per se is not enough to explain its
biological effects. To understand these effects, it is crucial to
achieve a comprehensive knowledge of the spatiotemporal pat-
tern of pathway activation. A paradigm for this is the activa-
tion of the Ras/ERK pathway, which leads to cell proliferation,
cell cycle arrest, or differentiation depending on the timing and
intensity of its activation (40, 41). Although the molecular
FIG. 4. Involvement of PKC in Ras activation by W13. A, NIH3T3 cells were serum-deprived for 24 h in serum-free medium () or 0.5%
FCS-containing medium () and then treated for 5 min with PDGF (1 nM), W12 (15 g/ml), or W13 (15 g/ml) in the absence () or presence ()
of GF109203X (5 M). B, quiescent NIH3T3 cells in a serum-free medium were treated for 5 min with PDGF (1 nM), W12 (15 g/ml), or W13 (15
g/ml) in the absence () or presence () of TPA (100 nM). C, cells were treated as described in B but with TPA in all cases. Where indicated, 5
M Ro-0432 (Ro) or 5 M GF109203X (GF) were added 15 min prior to the addition of W13 and TPA. In A, B, and C, Ras activation was measured
by GST-RBD pull-down followed by Western blot with anti-(pan)-Ras antibodies (upper panel). An aliquot of each lysate was also loaded in another
gel to analyze total Ras protein levels (lower panel). D, quantification of three different experiments, including the results shown in A, B, and C.
FIG. 5. Activation of Ras by TPA and W13 treatment does not
require EGF or PDGF receptor activity. Quiescent NIH3T3 cells
were incubated in serum-free medium for 2 h and pre-incubated () or
not pre-incubated () with AG1296 or AG1478 for 30 min as indicated.
Cells were then treated with EGF (25 ng/ml) or PDGF (1 nM) as controls
or with TPA (100 nM) together with W12 (15 g/ml) or W13 (15 g/ml).
Ras activation was measured by GST-RBD pull-down followed by West-
ern blot with anti-(pan)-Ras antibodies (upper panel). An aliquot of each
lysate was also loaded in another gel to analyze total Ras protein levels
(lower panel). The experiment was repeated three times with similar
results
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mechanisms involved in Ras activation have been intensively
studied over the past decade, it is not yet completely under-
stood which mechanisms govern Ras inactivation and, hence,
its global signaling output in response to given stimuli. We
have previously shown that CaM is essential for the impair-
ment of Ras activation at low concentrations of growth factors
in fibroblasts. Furthermore, CaM is important to ensure an
appropriate signaling level of the ERK cascade in these cells, as
CaM inhibition prior to mitogenic stimulation leads to a more
sustained ERK activation and to accumulation of the CDK
inhibitor p21cip1 (27). CaM is able to specifically impair K-Ras
activation but not the activation of the other Ras isoforms, and
this is most probably through its direct binding to GTP-bound
K-RasB (28). To gain insight into the mechanism of how CaM is
able to down-regulate the Ras/ERK pathway, we have analyzed
the nature of the signals that are essential to induce the acti-
vation of this pathway in cooperation with CaM inhibition.
As we had shown previously, low doses of serum, EGF,
PDGF, and bombesin were all able to induce ERK activation in
the presence of CaM inhibitors (28). These results suggested
that an intracellular regulator of the Ras/ERK pathway, acti-
vated by all the above stimuli, was able to activate the Ras/
ERK pathway when CaM was inhibited. Protein kinase C has
been shown to be a regulator of the Ras/ERK signaling path-
way that is able to regulate different levels of this pathway. In
many cell types, conventional PKC activation by phorbol ester
treatment induces a potent activation of ERK, but there are
multiple upstream inputs of PKC in this pathway regarding
the cell type. For instance, examples of the activation of Ras,
Raf, or MEK by PKC have all been described using different
cell systems (20, 21, 42, 43). Therefore, we tested whether PKC
was involved in the activation of ERK that CaM inhibitors were
able to induce in the presence of low concentrations of growth
factors in both NIH3T3 and Swiss 3T3 cells. Incubation with
the broad spectrum PKC inhibitor GF109203X blocked ERK
activation induced by W13 in Swiss 3T3 cells. Similarly, in
NIH3T3 cells treated with either GF109203X, Ro-0432, or,
chronically, TPA, the activation of ERK by W13 was also
blocked. These results suggested that PKC was necessary for
the observed activation of ERK under our experimental
conditions.
CaM most probably regulates the Ras/ERK pathway at the
level of Ras, because we have shown that CaM binds specifi-
cally to GTP-bound K-RasB and that W13 treatment ultimately
leads to K-Ras activation. However, the requirement for PKC
activity to observe ERK activation in response to CaM inhibi-
tion could merely reflect the ability of PKC to activate different
levels of this pathway downstream of Ras. To address this
issue, we analyzed the effects of PKC inhibition on the activa-
tion of Raf-1 and Ras by W13 treatment in NIH3T3. As we had
shown previously (27), treatment with W13 induces Raf-1 ki-
nase activity in serum-starved NIH3T3 cells. Interestingly,
PKC inhibition completely prevented W13-induced activation
of Raf-1. These results indicated that the PKC-dependent step
in W13-induced ERK activation was at least at the level of
Raf-1. We finally tested whether Ras activation by W13 was
also PKC-dependent. PKC inhibition in serum-starved NIH3T3
completely prevented the activation of Ras by W13 under both
0 and 0.5% FCS. This indicated that PKC was necessary for
CaM inhibition to induce Ras activation, thereby placing PKC-
dependence at the level of Ras.
PKC activity was therefore necessary for the observed acti-
vation of the Ras/ERK pathway in response to CaM inhibition
under low concentrations of growth factors. Altogether, these
results suggested that CaM was preventing Ras activation by
PKC in these cells. Thus, under CaM-inhibited conditions, dif-
ferent sources of PKC activity such as the growth factors tested
to date were able to induce Ras activation. We therefore ana-
lyzed whether PKC activation by TPA treatment alone instead
of growth factor treatment was able to cooperate with CaM
inhibitors to induce Ras activation in NIH3T3 cells. Interest-
ingly, in these cells PKC activation by TPA is not able to
promote Ras activation as measured by the “classic” nucleotide
labeling method, although it induces potently ERK activation
(20). Using the RBD pull-down method, we confirmed that TPA
was unable to induce Ras activation in NIH3T3 cells. The
inability of PKC activity alone to promote Ras activation ruled
out the possibility that the effect of W13 was to induce PKC
activation and, consequently, activation of the Ras/ERK path-
way. In sharp contrast, TPA treatment in a CaM-inhibited
background induced a robust activation of Ras at levels com-
parable with those achieved by PDGF treatment. These results
suggested that CaM was essential in preventing the activation
of Ras by PKC in these cells. Regarding the physiological role of
FIG. 8. Models of CaM and PKC cooperation in Ras activity
regulation. a, CaM-bound K-Ras-GTP may be insensitive to or inhibit
GAP inhibition by PKC. b, PKC may have a positive effect on K-Ras-
GTP signaling, but this effect is inhibited in the presence of CaM.
FIG. 6. Activation of Ras by TPA and W13 is specific for K-Ras.
Quiescent NIH3T3 cells were treated for 5 min with PDGF (1 nM), TPA
(100 nM), W12 (15 g/ml), W13 (15 g/ml), or TPA plus W12 (15 g/ml)
or W13 (15 g/ml). Ras activation was measured by GST-RBD pull-
down followed by Western blot with specific antibodies for the three Ras
isoforms (upper panel). An aliquot of each lysate was also loaded in
another gel and Western blotted with anti-pan Ras as a control of the
amount of Ras per lysate (lower panel). The experiment was repeated
three times with similar results
FIG. 7. Calmodulin inhibits in vitro phosphorylation of K-Ras
by PKC. Purified K-Ras-GST expressed in baculovirus was phospho-
rylated in vitro with the catalytic subunit of PKC in the presence of
[-32P]ATP as indicated under “Experimental Procedures.” Where indi-
cated, K-Ras-GST was preincubated (10 min) with CaM (7 g) in the
presence of either Ca2 or EGTA. Digital image obtained with a phos-
phorimaging device is shown.
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this effect of CaM on Ras activation by PKC, this would be
relevant in circumstances wherein cells need to keep PKC
active but Ras should be down-regulated. For instance, after
proliferative activation of the cells, PKC activity is more sus-
tained than that of Ras. We hypothesize that CaM is essential
for turning off Ras in an environment wherein PKC activity is
high, such as in mitogenically stimulated fibroblasts. If PKC
activity was not uncoupled to Ras activation in these cells, an
excessively sustained ERK activity could lead to cell cycle ar-
rest through p21cip1 up-regulation.
It has been reported that CaM inhibitors can induce cleavage
of membrane-bound proteins (30), a process that is also influ-
enced by PKC (37, 38, 44), leading to the possibility that TPA,
together with W13, was inducing Ras/ERK activation via the
shedding of membrane-bound, pro-growth factors. The inhibi-
tion of both the EGF and PDGF receptor tyrosine kinases
demonstrated that Ras activation by TPA together with W13
was independent of the kinase activity of these tyrosine kinase
receptors and thus independent of their extracellular stimula-
tion or intracellular transactivation by a PKC-dependent
mechanism.
As we had shown previously, CaM interacts specifically with
K-Ras and inhibits its activation (28). We therefore investi-
gated whether PKC activation, together with CaM inhibition,
was able to differentially activate Ras isoforms. As expected,
TPA plus W13 induced K-Ras activation nicely but did not
induce H- or N-Ras activation. This indicated that the interplay
between CaM and PKC in regulating Ras at the molecular level
was highly specific, as it was restricted only to K-Ras (consist-
ent with our previous observations). Two models for the possi-
ble cooperation between CaM inhibition and PKC activity in
K-Ras activation that are in concordance with the results pre-
sented up to now are shown in Fig. 7.
The mechanistic links lying between PKC and Ras still re-
main to be characterized in most of the cells types in which Ras
is activated by PKC, as this has only been elucidated in T
lymphocytes. In these cells, TPA stimulation leads to a very
potent activation of Ras, and this has been shown to rely on
GAP inhibition (19). It should be noted, however, that lympho-
cytes express RasGRPs, a novel class of nucleotide exchange
factors that are regulated by diacylglycerol, and will probably
cooperate in the activation of Ras by phorbol esters in lympho-
cytes (45). Although there are a few studies of other cell types
that suggest that PKC induces GAP inhibition (46–48), there is
still no compelling evidence to propose a general role for GAP
inhibition in Ras activation by PKC other than in T lympho-
cytes. Moreover, there is very little information regarding iso-
form specificity in Ras regulation by PKC, as this has only been
investigated in COS cells. In these cells, TPA induces H-, N-,
and K-Ras activation (21), highlighting the mechanistic differ-
ences that must exist between COS and NIH3T3 cells. In
NIH3T3 cells, it has been proposed that TPA induces Ras/ERK
pathway activation upstream of Shc phosphorylation and its
association with Grb-2 (49). However, these conclusions are
made on the basis of the use of dominant negative Ras and Sos
proteins, but no measurements of Ras activation are shown. We
have clearly demonstrated that TPA does not induce Ras acti-
vation in NIH3T3 cells, and the use of RasN17 has proven not
to be a reliable tool when studying Ras involvement in a sig-
naling pathway (21, 50).
A strikingly direct link between PKC and K-RasB but not the
other Ras isoforms was shown several years ago when PKC
induced the direct phosphorylation of K-RasB (51). Our results
showed that this phosphorylation could be inhibited in vitro by
CaM. Consequently, we favor the hypothesis that PKC phos-
phorylation of K-Ras is somehow activating its downstream
signaling and that this effect would be prevented by CaM
binding to K-Ras (Fig. 8b). However, the physiological conse-
quences of this phosphorylation are not yet clear, and further
work is needed to prove this hypothesis.
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